Xeris Biopharma Holdings Inc [XERS] stock prices are down -2.01% to $3.42 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The XERS shares have gain 1.48% over the last week, with a monthly amount glided 12.50%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on November 11, 2024, when Piper Sandler downgraded its rating to a Neutral but kept the price target unchanged to $3 for it. Previously, Oppenheimer started tracking the stock with Outperform rating on March 28, 2024, and set its price target to $5. On August 28, 2023, Craig Hallum initiated with a Buy rating and assigned a price target of $4.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $4 on October 21, 2022. Craig Hallum initiated its recommendation with a Buy and recommended $6.50 as its price target on April 28, 2022. SVB Leerink started tracking with a Outperform rating for this stock on November 17, 2021, and assigned it a price target of $6. In a note dated October 29, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
The stock price of Xeris Biopharma Holdings Inc [XERS] has been fluctuating between $1.69 and $3.87 over the past year. Currently, Wall Street analysts expect the stock to reach $5.8 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $3.42 at the most recent close of the market. An investor can expect a potential return of 69.59% based on the average XERS price forecast.
Analyzing the XERS fundamentals
The Xeris Biopharma Holdings Inc [NASDAQ:XERS] reported sales of 187.36M for trailing twelve months, representing a surge of 12.31%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.24%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is 3.97 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -8.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.33 points at the first support level, and at 3.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.49, and for the 2nd resistance point, it is at 3.57.
Ratios To Look Out For
It’s worth pointing out that Xeris Biopharma Holdings Inc [NASDAQ:XERS]’s Current Ratio is 1.79. On the other hand, the Quick Ratio is 1.29, and the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 2.79.
Transactions by insiders
Recent insider trading involved Schmid John P., Director, that happened on Aug 12 ’24 when 4515.0 shares were purchased. Director, Schmid John P. completed a deal on Aug 09 ’24 to buy 4285.0 shares. Meanwhile, Director Schmid John P. bought 5400.0 shares on May 10 ’24.
